160
1.
Meyers SM, Greene T, Gutman FA. A twin study of age-related
macular degeneration. Am J Ophthalmol 1995; 120 (6): 757-766.
2.
Congdon N, O’Colmain B, Klaver CC, Klein R, Munoz B,
Friedman DS, Kempen J, Taylor HR, Mitchell P. Causes and
prevalence of visual impairment among adults in the United
States. Arch Ophthalmol 2004; 122 (4): 477-485.
3.
Ferris FL, III, Fine SL, Hyman L. Age-related macular degenera-
tion and blindness due to neovascular maculopathy. Arch Oph-
thalmol 1984; 102 (11): 1640-1642.
4.
Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE,
Hofman A, Jensen S, Wang JJ, de Jong PT. Risk factors for age-
related macular degeneration: Pooled findings from three conti-
nents. Ophthalmology 2001; 108 (4): 697-704.
5.
Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G,
Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R. An inter-
national classification and grading system for age-related macu-
lopathy and age-related macular degeneration. The International
ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39
(5): 367-374.
6.
Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-re-
lated maculopathy in Australia. The Blue Mountains Eye Study.
Ophthalmology 1995; 102 (10): 1450-1460.
7.
VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR,
McCarty CA. The prevalence of age-related maculopathy: the
visual impairment project. Ophthalmology 2000; 107 (8): 1593-
1600.
8.
Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE,
Hofman A, Jensen S, Wang JJ, de Jong PT. Risk factors for age-
related macular degeneration: Pooled findings from three conti-
nents. Ophthalmology 2001; 108 (4): 697-704.
9.
Tomany SC, Wang JJ, van Leeuwen R, Klein R, Mitchell P,
Vingerling JR, Klein BE, Smith W, de Jong PT. Risk factors for
incident age-related macular degeneration: pooled findings from
3 continents. Ophthalmology 2004; 111 (7): 1280-1287.
10. The Age-Related Eye Disease Study Research Group. The Age-
Related Eye Disease Study (AREDS): design implications. AREDS
Report No. 1. Control Clin Trials 1999; 20 (6): 573-600.
11. Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, Lindblad
AS, Milton RC, Bressler SB, Klein R, Age-Related Eye Disease
Study (AREDS) Research Group. A Simplified Severity Scale
for Age-Related Macular Degeneration: AREDS Report No. 18.
Arch Ophthalmol 2005; 123 (11): 1570-1574.
12. A randomized, placebo-controlled, clinical trial of high-dose sup-
plementation with vitamins C and E, beta carotene, and zinc for
age-related macular degeneration and vision loss: AREDS Report
No. 8. Arch Ophthalmol 2001; 119 (10): 1417-1436. Erratum
in: 2008; 126 (9): 1251.
13. A randomized, placebo-controlled, clinical trial of high-dose sup-
plementation with vitamins C and E, beta carotene, and zinc for
age-related macular degeneration and vision loss: AREDS Report
No. 8. Arch Ophthalmol 2001; 119 (10): 1417-1436. Erratum
in: 2008; 126 (9): 1251.
14. The effect of vitamin E and beta carotene on the incidence
of lung cancer and other cancers in male smokers.The Alpha-
Tocopherol,Beta Carotene Cancer Prevention Study Group. N
Engl J Med 1994; 330 (15): 1029-1035.
15. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen
MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH,
Barnhart S, Hammar S. Effects of a combination of beta carotene
and vitamin A on lung cancer and cardiovascular disease. N Engl
J Med 1996; 334 (18): 1150-1155.
16. Bone RA, Landrum JT, Tarsis SL. Preliminary identification of the
human macular pigment. Vision Res 1985; 25 (11): 1531-1535.
17. Rapp LM, Maple SS, Choi JH. Lutein and zeaxanthin concen-
trations in rod outer segment membranes from perifoveal and
peripheral human retina. Invest Ophthalmol Vis Sci 2000; 41
(5): 1200-1209.
18. Snodderly DM, Handelman GJ, Adler AJ. Distribution of indi-
vidual macular pigment carotenoids in central retina of macaque
and squirrel monkeys. Invest Ophthalmol Vis Sci 1991; 32 (2):
268-279.
19. Wisniewska A, Subczynski WK. Distribution of macular xan-
thophylls between domains in a model of photoreceptor outer
segment membranes. Free Radic Biol Med 2006; 41 (8): 1257-
1265.
20. Beatty S, Boulton M, Henson D, Koh HH, Murray IJ. Macular
pigment and age related macular degeneration. Br J Ophthalmol
1999; 83 (7): 867-877.
21. Landrum JT, Bone RA, Kilburn MD. The macular pigment: a
possible role in protection from age-related macular degenera-
tion. Adv Pharmacol 1997; 38: 537-556.
22. Johnson EJ, Hammond BR, Yeum KJ, Qin J, Wang XD, Castaneda
C, Snodderly DM, Russell RM. Relation among serum and tissue
concentrations of lutein and zeaxanthin and macular pigment den-
sity. Am J Clin Nutr 2000; 71 (6): 1555-1562.
23. Antioxidant status and neovascular age-related macular degenera-
tion. Eye Disease Case-Control Study Group. Arch Ophthalmol
1993; 111 (1): 104-109. Erratum in: Arch Ophthalmol 1993;
111 (11): 1499. Arch Ophthalmol 1993; 111 (9): 1228. Arch
Ophthalmol 1993; 111 (10): 1366.
24. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton
TC, Farber MD, Gragoudas ES, Haller J, Miller DT. Dietary
carotenoids, vitamins A, C, and E, and advanced age-related
macular degeneration. Eye Disease Case-Control Study Group.
JAMA 1994; 272 (18): 1413-1420. Erratum in: JAMA 1995;
273 (8): 622.
25. Bernstein PS, Zhao DY, Wintch SW, Ermakov IV, McClane RW,
Gellermann W. Resonance Raman measurement of macular caro-
tenoids in normal subjects and in age-related macular degeneration
patients. Ophthalmology 2002; 109 (10): 1780-1787.
26. Delcourt C, Carriere I, Delage M, Barberger-Gateau P, Schalch
W. Plasma lutein and zeaxanthin and other carotenoids as modi-
fiable risk factors for age-related maculopathy and cataract: the
POLA Study. Invest Ophthalmol Vis Sci 2006; 47 (6): 2329-
References:
